

-1-

Date: October 23, 2001 Express Mail Label No. E1005366900US

Inventors: Krzysztof B. Wicher, Olof Peder Holst, Maher Youssef Abou Hachem,
Eva Margareta Nordberg Karlsson and Gudmundur O. Hreggvidsson

Attorney's Docket No.: 2739.2001-001

THERMOSTABLE CELLULASE

RELATED APPLICATIONS

This application is a continuation-in-part of and claims priority to PCT Application No. PCT/IS01/00012, filed 15 June 2001 (in English), which is a continuation-in-part of U.S. Application No. 09/594,884, filed June 15, 2000; the entire teachings of the above applications are incorporated herein by reference.

mm
5/21/03 5

BACKGROUND OF THE INVENTION

Cellulases are enzymes that are capable of hydrolyzing cellulose. The products of the reaction include cellobiose and glucose which can be used for a variety of 10 applications. For example, glucose obtained by cellulase catalyzed hydrolysis of plant cellulose can be fermented to produce ethanol which can be used as a fuel.

Cellulases can also be used in the de-inking and refining of recycled paper. Enzymes with high thermal stability are particularly useful in these applications because elevated temperatures are commonly used in these processes. Thermostable cellulases 15 are also useful in the consumer products and food industries, for example, in extracting and clarifying juice from fruits or vegetables. Cellulases and particularly thermostable cellulases also have applications in the textile and laundry industries. For example, the enzyme can be used to remove microfibers from the surface of cotton garments (or other garments made of cellulose based fabric), thereby brightening the color and removing

the dull look that comes with wear. Cellulases are also useful for cleaning garments, for example as additives to detergents and for producing a "stone-washed" effect on indigo dyed denim (see, U.S. Patent No. 4,912,056).

The development of thermostable cellulases with improved stability and/or
5 catalytic properties would provide advantages for the above-referenced applications and certain other applications. Therefore, a need exists for improved thermostable cellulases which can be easily produced.

SUMMARY OF THE INVENTION

The invention relates to polypeptides having thermostable cellulase activity.
10 The polypeptides of the invention are variants of full-length or naturally occurring proteins that have thermostable cellulase activity and are readily produced in large quantities by expression in a host cell such as *Escherichia coli*. In one embodiment, the polypeptide is a variant of a glycosyl hydrolase of family 12 wherein one or more of the amino acid residues that are not part of the catalytic domain (e.g., one or more amino
15 acid residues in the amino terminal hydrophobic domain and/or linker moiety) are deleted. In preferred embodiments, the polypeptide is derived from a thermophilic organism from a *Rhodotermus* species such as *R. marinus*, *R. obamae*, and *R. obamensis*; or a *Pyrococcus* species, including *P. abyssi*, *P. endeavori*, *P. furiosus*, *P. horikoshi*, *P. shinkai*, and *P. woesei*. In a more particular embodiment, the polypeptide
20 comprises the amino acid sequence of SEQ ID NO:2 wherein one or more of the amino acid residues from position one to about position 40 are deleted. In even more particular embodiments, the polypeptide can have an amino acid sequence selected from residues 18-261 of SEQ ID NO:2, residues 19-261 of SEQ ID NO:2, residues 20-261 of SEQ ID NO:2, residues 21-261 of SEQ ID NO:2, residues 22-261 of SEQ ID NO:2,
25 residues 23-261 of SEQ ID NO:2, residues 24-261 of SEQ ID NO:2, residues 25-261 of SEQ ID NO:2, residues 26-261 of SEQ ID NO:2, residues 27-261 of SEQ ID NO:2, residues 28-261 of SEQ ID NO:2, residues 29-261 of SEQ ID NO:2, residues 30-261 of SEQ ID NO:2, residues 31-261 of SEQ ID NO:2, residues 32-261 of SEQ ID NO:2,

residues 33-261 of SEQ ID NO:2, residues 34-261 of SEQ ID NO:2, residues 35-261 of SEQ ID NO:2, residues 36-261 of SEQ ID NO:2, residues 37-261 of SEQ ID NO:2 or residues 38-261 of SEQ ID NO:2.

The polypeptides of the invention can have improved catalytic properties and/or 5 stability relative to full-length enzyme. In one embodiment, the polypeptide has a half-life of at least about 3.5 hours at 90°C. In another embodiment, the polypeptide has a specific activity that is at least about two times greater than the specific activity of a protein consisting of the amino acid sequence of SEQ ID NO:2.

In particularly preferred embodiments, the polypeptide has the amino acid 10 sequence of residues 18-261 of SEQ ID NO:2 or the amino acid sequence of residues 38-261 of SEQ ID NO:2.

The invention also relates to isolated nucleic acids which encode a polypeptide of the invention and to constructs which comprises an isolated nucleic acid of the invention that is operatively linked to one or more regulatory sequences.

15 The invention also relates to host cells which comprise an isolated nucleic acid or construct of the invention, and to a method of producing a polypeptide having thermostable cellulase activity. In one embodiment, the method comprises maintaining a host cell of the invention under conditions suitable for expression of the polypeptide that has thermostable cellulase activity.

20 BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention.

Fig. 1 is a graph illustrating the growth of *Escherichia coli* (*E. coli*) strain 25 BL21(DE3) transfected with constructs encoding full-length Cel12A or δCEL12AH. Expression of Cel12A or δCEL12AH was induced by adding isopropyl β-D-thio-galactopyranoside (IPTG) to the cultures (time of addition of IPTG marked with the arrow). Cultures containing cells transfected with the construct encoding

full-length Cel12A were induced () or not induced (○), and cultures containing cells transfected with the construct encoding δCEL12AH were induced (▲) or not induced (△). Induction of expression of full-length Cel12A (●) resulted in a decrease in the OD₆₀₀.

5 Fig. 2 is a photograph of an SDS-polyacrylamide gel stained with Coomassie brilliant blue G250. *E. coli* expression constructs encoding full-length Cel12A or variants thereof were induced and harvested 2.5 hours later. Crude cell contents were separated by SDS-PAGE and visualized by staining. Lane 1, uninduced culture; Lane 2, cells induced to express full-length Cel12A; Lane 3, cells induced to express
10 Cel12A(sp-)H; Lane 4, cells induced to express δCel12AH.

Figs. 3A-3D are schematic representations of full-length Cel12A (A) and variants δCel12AH (B), Cel12A(sp-)H (C) and Cel12A(sp-) (D). S.P.- signal peptide. [EP]₄-linker moiety. C.D.- catalytic domain. H.t.-HSV-Tag. H6- hexa-histidine.

Fig. 4 is a graph showing the thermal unfolding curves for Cel12A(sp-)H (■)
15 and δCel12AH (△) measured by differential scanning calorimetry.

DETAILED DESCRIPTION OF THE INVENTION

A description of preferred embodiments of the invention follows.

Rhodothermus marinus (*R. marinus*) is a thermophilic heterotrophic slightly halophilic marine eubacterium growing optimally at 65°C. *R. marinus* produces several 20 thermostable glycosyl-hydrolases including a cellulase (Cel12A) (Hreggvíðsson, G.O., et al., *Applied and Environmental Microbiology*, 62:3047-3049 (1996)), which has been cloned in *Escherichia coli* (*E.coli*) and characterised (Halldorsdóttir, S. et al., *Appl Microbiol Biotechnol*, 49:277-284 (1998)). Cel12A, which belongs to family 12 glycosyl hydrolases, is among the most thermostable endo-cellulases, with maximal 25 catalytic activity at temperatures substantially higher than the optimal temperature for growth of *R. marinus*. Many of cellulases in this family (family 12 glycosyl hydrolases) contain a highly hydrophobic signal peptide (Garda, A.L. et al., *Biochem J.*,

324:403-411 (1997); Ooi, T. *et al.*, *Nucleic Acids Res.*, 18:5885 (1990)). Family 12 glycosyl-hydrolases catalyse the hydrolysis of β -1,4 glycosidic bonds primarily in mixed linkage (1-3),(1-4) β -D-glucans.

The invention relates to improved thermostable cellulases, nucleic acids and constructs (e.g., expression vectors) encoding the improved thermostable cellulases and to methods for producing the improved enzymes. As described herein, low yields of the thermostable cellulase Cel12A from *R. marinus* were obtained when a nucleic acid encoding the enzyme was expressed in *E. coli*. Low yields were obtained because the recombinant polypeptide was cytotoxic to the bacterial host cells. In addition, severe aggregation occurred when moderately high concentrations of the enzyme were heat treated at 65°C, which is the physiological temperature of *R. marinus*. Aggregation also occurred when the native protein was heated at 65°C. Analysis of the Cell12A sequence revealed that the protein, like certain other family 12 glycosyl hydrolases, comprises an amino terminal region that is highly hydrophobic (reminiscent of a signal peptide) and a catalytic domain which are linked by a linker moiety (e.g., region rich in proline, hydroxyamino acids (e.g., threonine, serine, tyrosine), alanine and/or glycine). Two variant polypeptides which lacked the amino-terminal hydrophobic region or the amino-terminal hydrophobic region and the linker moiety were produced in high yield when expressed in *E. coli*, indicating that cytotoxicity of Cel12A is mediated through the N-terminal hydrophobic region (putative signal peptide). The variant polypeptides were studied and their catalytic and physical properties compared to those of full-length Cel12A. The pH optima and substrate specificities of the variant polypeptides were the same as those of full-length Cel12A. However, the specific activities of the variants were about three fold higher than the specific activity of the full-length enzyme. Furthermore, the variant polypeptides were more stable than full-length Cel12A and had half-lives that exceeded 3 hours at 90°C and unfolding temperatures that were up to about 103°C.

Polypeptides

In one aspect, the invention relates to polypeptides that have thermostable cellulase activity. Preferably the polypeptides of the invention can hydrolyze β -1,4 bonds in β -1,4-linked and mixed linkage β -glucans (e.g., carboxymethyl cellulose, cellulose). The polypeptides of the invention have the amino acid sequence of a thermostable cellulase wherein one or more amino acids which are not part of the catalytic domain of the enzyme are deleted. The catalytic domain and other domains (e.g., signal peptide, linker domains) of a cellulase can be readily identified by analysis and comparison of the amino acid sequence of a thermostable cellulase with the sequences of other cellulases (see, for example, Henrissat, B., *Biochem J*, 280:309-316 (1991); Henrissat, B. *et al.*, *Biochem J*, 293:781-788 (1993)). For example, an amino acid sequence can be compared to the sequences in SWISS-PROT using a suitable comparison program, such as PROSITE (Hoffman, K. *et al.*, *Nucleic Acids Res*, 27:215-219 (1999)).

In one example, the polypeptide of the invention can be a variant of a thermostable cellulase which contains an amino terminal hydrophobic region and a catalytic domain that are linked by a linker moiety (e.g., region rich in proline and/or hydroxylamino acids (e.g., threonine, serine, tyrosine)), such as certain family 12 glycosyl hydrolases (e.g., Cel12A from *R. marinus*, EglA from *Pyrococcus furiosus* and the like). The polypeptide of this example can have the amino acid sequence of the native or full-length cellulase (e.g., Cel12A, EglA) wherein one or more of the amino acids in the amino-terminal hydrophobic domain and/or linker moiety are deleted. Preferably, the polypeptide of this example has the amino acid sequence of the native or full-length cellulase wherein the amino acids which constitute the amino terminal hydrophobic region (e.g., signal peptide) or the amino acids which constitute the amino terminal hydrophobic region and the linker moiety are deleted. In certain embodiments, the deleted amino acid residues comprise a region in the range of at least the first 17 amino acid residues and up to the first 37 amino acid residues of the corresponding full-length polypeptide.

The nucleotide sequence of a nucleic acid encoding Cel12A of *Rhodothermus marinus* is deposited in GenBank under accession number U72637, the entire teaching of which are incorporated herein by reference. However, the originally deposited sequence contained sequence errors which have been rectified in the sequence depicted 5 as (SEQ ID NO:1). Specifically, three nucleotides were missing, at positions 1019 (insert G), 1049 (insert C), 1093 (insert C), and positions 1467-68 CG should read GC and CG. The nucleic acid sequence (SEQ ID NO:1) has an open reading frame starting at position 710. The sequence of this open reading frame is presented herein as SEQ ID NO:3. The amino acid sequence of Cel12A of *Rhodothermus marinus* is presented 10 herein as SEQ ID NO:2. The amino terminal hydrophobic domain of the protein (SEQ ID NO:2) consists of amino acid residues 1 to about 17, the amino acid residues from about position 18 to about position 37 constitute the linker moiety and the residues from about position 38 to position 261 constitute the catalytic domain. Note that due to the 15 errors in the original DNA-sequence, the previously deposited amino acid sequence was erroneously assigned at residues 105-129.

In certain embodiments, the polypeptide of the invention has the amino acid sequence of Cel12A from *R. marinus* (SEQ ID NO:2) wherein one or more of the amino acid residues in the amino-terminal hydrophobic region and/or the linking moiety (positions 1 to about 40 of SEQ ID NO:2) are deleted. Preferably, the polypeptide of 20 the invention has the amino acid sequence of SEQ ID NO:2 wherein at least about five or at least about ten amino acid residues in the amino-terminal hydrophobic region and/or the linking moiety are deleted. More preferably, the polypeptide of the invention has the amino acid sequence of SEQ ID NO:2 wherein at least about 15, or at least about 17, or at least about 20, or at least about 25, or at least about 30, or at least about 25 35 or about 37 of the amino acid residues in the amino-terminal hydrophobic region and/or the linking moiety are deleted. In additional embodiments, the polypeptide having thermostable cellulase activity has an amino acid sequence selected from the group consisting of residues 18-261 of SEQ ID NO:2, residues 19-261 of SEQ ID NO:2, residues 20-261 of SEQ ID NO:2, residues 21-261 of SEQ ID NO:2, residues 22-261 of

SEQ ID NO:2, residues 23-261 of SEQ ID NO:2, residues 24-261 of SEQ ID NO:2, residues 25-261 of SEQ ID NO:2, residues 26-261 of SEQ ID NO:2, residues 27-261 of SEQ ID NO:2, residues 28-261 of SEQ ID NO:2, residues 29-261 of SEQ ID NO:2, residues 30-261 of SEQ ID NO:2, residues 31-261 of SEQ ID NO:2, residues 32-261 of
5 SEQ ID NO:2, residues 33-261 of SEQ ID NO:2, residues 34-261 of SEQ ID NO:2, residues 35-261 of SEQ ID NO:2, residues 36-261 of SEQ ID NO:2, residues 37-261 of SEQ ID NO:2 and residues 38-261 of SEQ ID NO:2. In more particular embodiments, the amino terminal amino acid residue of the polypeptide is methionyl. For example, the polypeptide can have the sequence of SEQ ID NO:2 wherein residues 2-17 or
10 residues 2-37 are deleted. In another example, the amino acid sequence of the polypeptide is methionyl-residues 18-261 of SEQ ID NO:2 wherein the methionyl is the amino terminal residue of the polypeptide.

In a particularly preferred embodiment, the polypeptide having thermostable cellulase activity has the amino acid sequence of SEQ ID NO:2 wherein residues 2-17 or residues 2-37 are deleted.

Further encompassed by the present invention are thermostable cellulase active polypeptides with substantial sequence identity to SEQ ID NO: 2, wherein one or more of the first 37 amino acid residues of the full-length sequence are deleted, such as e.g., the first 17 amino acids (the hydrophobic amino terminal region), and/or a portion of or
20 all of the linker moiety comprising residues from about 18-37. Substantial sequence identity in this context is meant to include at least about 85% identity, preferably at least about 90% identity, such as about 95% or 97% identity, and also including about 99% sequence identity. "Sequence identity" as used herein is calculated based on a reference sequence, (which in this instance is the sequence of SEQ ID NO: 2). Algorithms for
25 sequence analysis are known in the art, such as BLAST, described in Altschul *et al.*, *J. Mol. Biol.*, 215:403-10 (1990). Generally, the default settings with respect to e.g. "scoring matrix" and "gap penalty" will be used for alignment.

In additional embodiments, the polypeptide of the invention is a family 12 glycosyl hydrolase having the amino acid sequence of EglA from *Pyrococcus furiosus*

(SEQ ID NO:5) wherein one or more of the amino acid residues in the amino-terminal hydrophobic region and/or the linking moiety are deleted. The nucleotide sequence (SEQ ID NO:4) of a nucleic encoding EglA from *Pyrococcus furiosus* is deposited in GenBank under accession number AF181032, the entire teaching of which are

- 5 incorporated herein by reference. The nucleic acid sequence (SEQ ID NO:4) has an open reading frame starting at position 82. The amino acid sequence of EglA from *Pyrococcus furiosus* is presented herein as SEQ ID NO:5. The amino terminal hydrophobic domain of EglA consists of amino acid residues 1 to about 19 and the amino acid residues from about position 28 to about position 49 constitute the linker
10 moiety (Bauer, M.W. et al., *J Bacteriology*, 181:284-290 (1999)). Accordingly, the polypeptide of the invention can comprise the amino acid sequence of residues 20 to 319 of SEQ ID NO:5 or the amino acid sequence of residues 50 to 319 of SEQ ID NO:5, for example.

- Also encompassed by the present invention are thermostable cellulase active
15 polypeptides with substantial sequence identity to SEQ ID NO: 5, wherein one or more of the first 49 amino acid residues (the hydrophobic amino terminal region and linker moiety) of the full-length sequence are deleted, such as e.g. the first 19 amino acids (the hydrophobic amino terminal region), and/or a portion of or all of the linker moiety comprising residues from about 20-49, where substantial sequence identity is defined as
20 above.

- The polypeptides of the invention can have improved characteristics, such as increased stability (e.g., thermal stability, detergent stability), increased solubility in aqueous solvents, increased catalytic activity (e.g., specific activity, catalytic rate) and/or reduced cytotoxicity relative to the native or full-length thermostable cellulase,
25 but retain the substrate specificity of the native or full-length cellulase. Accordingly, the polypeptides of the invention provide many advantages over certain other thermostable cellulases. For example, as described herein large quantities of the polypeptides of the invention can be produced by expression in *E. coli*, or other host cells, including other bacterial cells, yeast cells or cells of a filamentous fungus. Examples of suitable

bacterial cells besides *E.coli*, are *Bacillus spp.*, *Lactobacillus spp.* and *Zymomonomas spp.*; and of yeast cells are e.g., those of *Saccharomyces spp.* (particularly *S. cerevisiae*), *Schizosaccharomyces spp.*, and *Pichia spp.*; and useful cells of filamentous fungus include those from *Aspergillus spp.* such as *A. niger*, *A. nidulans* and *A. oryzae*; and

- 5 *Neurospora spp.*, e.g., *Neurospora crassa*.

In one embodiment, the polypeptide of the invention has enhanced stability (e.g., thermal stability, detergent stability, longer shelf life) relative to the corresponding full-length cellulase. For example, the catalytic activity of the polypeptide of the invention can have a half-life that is about 1.5, about two or more times longer than the 10 half-life of the full-length enzyme under certain conditions (e.g., storage at 4°C, heating to 90°C). In a particular embodiment, the catalytic activity of the polypeptide of the invention has a half-life of at least about 2.5 hours at 90°C. Preferably, the catalytic activity of the polypeptide of the invention has a half-life of at least about 3 hours, or about 5 hours, or about 10 hours or more at 90°C.

15 In another embodiment, the polypeptide of the invention has enhanced specific activity relative to the corresponding full-length cellulase. For example, the specific activity of the polypeptide of the invention can be about 1.5 or about two or more times greater than the specific activity of the corresponding full-length cellulase. In a particular embodiment, the specific activity of the polypeptide of the invention is at least 20 about two times greater than the specific activity of the corresponding full-length cellulase. Preferably, the specific activity of the polypeptide of the invention is at least about 3, or about 5 or more times greater than the specific activity of the corresponding full-length cellulase. The specific activity of the polypeptide of the invention and of full-length cellulases can be determined using any suitable method, such as the method 25 described herein. Preferably, the specific activity is determined using carboxymethyl cellulose as the substrate.

The polypeptide of the invention can be a fusion protein comprising a polypeptide having thermostable cellulase activity as described herein which is fused to a second moiety not occurring in the cellulase as found in nature. Thus, the second

moiety can be an amino acid, oligopeptide or polypeptide. The second moiety can be linked to the first moiety at a suitable position, for example, the N-terminus, the C-terminus or internally. In one embodiment, the fusion protein comprises an affinity ligand (e.g., an enzyme, an antigen, epitope tag (e.g., hemagglutinin (HA), HSV-Tag

5 (SQPELAPEDPED (SEQ ID NO:6)), polyhistidine (e.g., His₆), a binding domain) as the first moiety, and a second moiety comprising a linker sequence and polypeptide that has thermostable cellulase activity as described herein. Additional (e.g., third, fourth) moieties can be present as appropriate. When the polypeptide is produced as a fusion protein, the fusion partner (e.g., HA, HSV-Tag, His₆) can be used to facilitate

10 purification and/or isolation. If desired, the fusion partner can then be removed from polypeptide of the invention (e.g., by proteolytic cleavage).

Nucleic acids and Constructs

The invention also relates to isolated nucleic acids and to constructs comprising the nucleic acids. The nucleic acids of the invention can be DNA or RNA, for example, mRNA. The nucleic acid molecules can be double-stranded or single-stranded; single stranded RNA or DNA can be either the coding, or sense, strand or the non-coding, or antisense, strand. Preferably, the nucleic acids encode a polypeptide of the invention. If desired, the nucleotide sequence of the isolated nucleic acid can include additional non-coding sequences such as non-coding 3' and 5' sequences (including regulatory sequences, for example). Additionally, the nucleic acids of the invention can be fused to a nucleic acid comprising a marker sequence, for example, a nucleotide sequence which encodes a polypeptide to assist in isolation or purification of the polypeptide. Representative sequences include, but are not limited to, those which encode a glutathione-S-transferase (GST) fusion protein, a poly-histidine (e.g., His₆),

20 hemagglutinin, HSV-Tag, for example.

The nucleic acid molecules of the invention are "isolated" as used herein, an "isolated" nucleic acid molecule or nucleotide sequence is intended to mean a nucleic acid molecule or nucleotide sequence which is not flanked by nucleotide sequences

which normally flank the gene or nucleotide sequence (as in genomic sequences) and/or has been completely or partially purified from other nucleic acids (e.g., as in an DNA or RNA library). For example, an isolated nucleic acid of the invention may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs. In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstance, the material may be purified to essential homogeneity, for example as determined by PAGE or column chromatography such as HPLC. Thus, an isolated nucleic acid molecule or nucleotide sequence can include a nucleic acid molecule or nucleotide sequence which is synthesized chemically, using recombinant DNA technology or using any other suitable method. Therefore, a recombinant nucleic acid (e.g., DNA, RNA) contained in a vector is included in the definition of "isolated" as used herein. Also, isolated nucleotide sequences include recombinant nucleic acid molecules (e.g., DNA, RNA) in heterologous organisms, as well as partially or substantially purified nucleic acids in solution. *In vivo* and *in vitro* RNA transcripts of a DNA molecule of the present invention are also encompassed by "isolated" nucleotide sequences.

The present invention also pertains to nucleotide sequences which are not necessarily found in nature but which encode a polypeptide of the invention. For example, DNA molecules which comprise a sequence which is different from the naturally-occurring nucleotide sequence (e.g., SEQ ID NO:3) but which, due to the degeneracy of the genetic code, encode a polypeptides of the invention are the subject of this invention. The invention also encompasses variations of the nucleotide sequences of the invention, such as those encoding active fragments or active derivatives of the polypeptides as described below. Such variations can be naturally-occurring, or non-naturally-occurring, such as those induced by various mutagens and mutagenic processes. Intended variations include, but are not limited to, addition, deletion and substitution of one or more nucleotides which can result in conservative or non-conservative amino acid changes, including additions and deletions. Preferably, the

nucleotide or amino acid variations that are within the catalytic domain are silent or conserved; that is, they do not alter the improved characteristics or activity of the encoded polypeptide.

The invention described herein also relates to fragments of the isolated nucleic acid molecules described herein. The term "fragment" is intended to encompass a portion of a nucleotide sequence described herein which is from at least about 25 contiguous nucleotides to at least about 50 contiguous nucleotides or longer in length; such fragments are useful as probes and also as primers. Particularly preferred primers and probes selectively hybridize to the nucleic acid molecule encoding the polypeptides described herein. For example, fragments which encode polypeptides that retain activity, as described below, are particularly useful.

The invention also pertains to nucleic acid molecules which hybridize under high stringency hybridization conditions, such as for selective hybridization, to a nucleotide sequence described herein (e.g., nucleic acid molecules which specifically 15 hybridize to a nucleotide sequence encoding polypeptides described herein and encode a polypeptide having thermostable cellulase activity). Hybridization probes include synthetic oligonucleotides which bind in a base-specific manner to a complementary strand of nucleic acid. Suitable probes include polypeptide nucleic acids, as described in Nielsen *et al.*, *Science*, 254:1497-1500 (1991).

Such nucleic acid molecules can be detected and/or isolated by specific hybridization (e.g., under high stringency conditions). "Stringency conditions" for hybridization is a term of art which refers to the incubation and wash conditions, e.g., conditions of temperature and buffer concentration, which permit hybridization of a particular nucleic acid to a second nucleic acid; the first nucleic acid may be perfectly 25 (i.e., 100%) complementary to the second, or the first and second may share some degree of complementarity which is less than perfect (e.g., 60%, 75%, 85%, 95%). For example, certain high stringency conditions can be used which distinguish perfectly complementary nucleic acids from those of less complementarity.

"High stringency conditions", "moderate stringency conditions" and "low stringency conditions" for nucleic acid hybridizations are explained on pages 2.10.1-2.10.16 and pages 6.3.1-6 in *Current Protocols in Molecular Biology* (Ausubel, F.M. et al., "Current Protocols in Molecular Biology", John Wiley & Sons, (1998)) the 5 teachings of which are hereby incorporated by reference. The exact conditions which determine the stringency of hybridization depend not only on ionic strength (e.g., 0.2XSSC, 0.1XSSC), temperature (e.g., room temperature, 42°C, 68°C) and the concentration of destabilizing agents such as formamide or denaturing agents such as SDS, but also on factors such as the length of the nucleic acid sequence, base 10 composition, percent mismatch between hybridizing sequences and the frequency of occurrence of subsets of that sequence within other non-identical sequences. Thus, high, moderate or low stringency conditions can be determined empirically.

By varying hybridization conditions from a level of stringency at which no hybridization occurs to a level at which hybridization is first observed, conditions which 15 will allow a given sequence to hybridize (e.g., selectively) with the most similar sequences in the sample can be determined.

Exemplary conditions are described in Krause, M.H. and S.A. Aaronson, *Methods in Enzymology*, 200:546-556 (1991). Also, in, Ausubel, et al., "Current Protocols in Molecular Biology", John Wiley & Sons, (1998), which describes the 20 determination of washing conditions for moderate or low stringency conditions. Washing is the step in which conditions are usually set so as to determine a minimum level of complementarity of the hybrids. Generally, starting from the lowest temperature at which only homologous hybridization occurs, each degree (°C) by which the final wash temperature is reduced (holding SSC concentration constant) allows an 25 increase by 1% in the maximum extent of mismatching among the sequences that hybridize. Generally, doubling the concentration of SSC results in an increase in T_m of -17EC. Using these guidelines, the washing temperature can be determined empirically for high, moderate or low stringency, depending on the level of mismatch sought.

For example, a low stringency wash can comprise washing in a solution containing 0.2XSSC/0.1% SDS for 10 min at room temperature; a moderate stringency wash can comprise washing in a prewarmed solution (42°C) solution containing 0.2XSSC/0.1% SDS for 15 min at 42°C; and a high stringency wash can comprise 5 washing in prewarmed (68°C) solution containing 0.1XSSC/0.1%SDS for 15 min at 68°C. Furthermore, washes can be performed repeatedly or sequentially to obtain a desired result as known in the art.

Equivalent conditions can be determined by varying one or more of the parameters given as an example, as known in the art, while maintaining a similar degree 10 of identity or similarity between the target nucleic acid molecule and the primer or probe used. Hybridizable nucleotide sequences are useful as probes and primers for identification of organisms (e.g., recombinant bacteria) containing a nucleic acid of the invention and to isolate a nucleic acid of the invention, for example. As used herein, the term "primer" refers to a single-stranded oligonucleotide (e.g., synthetic oligo 15 deoxyribonucleotide) which acts as a point of initiation of template-directed DNA synthesis under appropriate conditions (e.g., in the presence of four different nucleoside triphosphates and an agent for polymerization, such as, DNA or RNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature. The appropriate length of a primer depends on the intended use of the primer, but typically 20 ranges from 15 to 30 nucleotides. Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. A primer need not reflect the exact sequence of the template, but must be sufficiently complementary to hybridize with a template. The term "primer site" refers to the area of the target DNA to which a primer hybridizes. The term "primer pair" refers to a set of 25 primers including a 5' (upstream) primer that hybridizes with the 5' end of the DNA sequence to be amplified and a 3' (downstream) primer that hybridizes with the complement of the 3' end of the sequence to be amplified.

The invention also pertains to nucleotide sequences which have substantial identity with the nucleotide sequences described herein; particularly preferred are

nucleotide sequences which have at least about 10%, preferably at least about 20%, more preferably at least about 30%, more preferably at least about 40%, even more preferably at least about 50%, yet more preferably at least about 70%, still more preferably at least about 80%, and even more preferably at least about 90% or 95%

- 5 identity, with nucleotide sequences described herein. Particularly preferred in this instance are nucleotide sequences encoding polypeptides having thermostable cellulase activity and an amino acid sequence described herein.

To determine the percent identity of two nucleotide sequences, the sequences can be aligned for optimal comparison purposes (e.g., gaps can be introduced in the
10 sequence of a first nucleotide sequence). The nucleotides at corresponding nucleotide positions can then be compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., %
15 identity = # of identical positions/total # of positions x 100).

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:5873-5877 (1993). Such an algorithm is
20 incorporated into the NBLAST program which can be used to identify sequences having the desired identity to nucleotide sequences of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, *Nucleic Acids Res*, 25:3389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g.,
25 NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>. In one embodiment, parameters for sequence comparison can be set at W=12. Parameters can also be varied (e.g., W=5 or W=20). The value "W" determines how many continuous nucleotides must be identical for the program to identify two sequences as containing regions of identity.

mmj
5/14/03

In certain embodiments, the isolated nucleic acid encodes a polypeptide having the amino acid sequence of Cel12A from *R. marinus* (SEQ ID NO:2) wherein one or more of the amino acid residues in the amino-terminal hydrophobic region and/or the linking moiety (positions 1 to about 37 of SEQ ID NO:2) are deleted. Preferably, the

5 isolated nucleic acid encodes a polypeptide having the amino acid sequence of SEQ ID NO:2 wherein at least about five or at least about ten amino acid residues in hydrophobic region and/or the linking moiety are deleted. More preferably, the isolated nucleic acid encodes a polypeptide having the amino acid sequence of SEQ ID NO:2 wherein at least about 15, or at least about 17, or at least about 20, or at least about 25,

10 or at least about 30, or at least about 35 or about 37 of the amino acid residues in hydrophobic region and/or the linking moiety are deleted. In additional embodiments, the isolated nucleic acid of the invention encodes a polypeptide having thermostable cellulase activity, and has a nucleotide sequence selected from the group consisting of nucleotides 52-783 of SEQ ID NO:3, nucleotide 55-783 of SEQ ID NO:3, nucleotides

15 58-783 of SEQ ID NO:3, nucleotides 61-783 of SEQ ID NO:3, nucleotides 64-783 of SEQ ID NO:3, nucleotides 67-783 of SEQ ID NO:3, nucleotides 70-783 of SEQ ID NO:3, nucleotides 73-783 of SEQ ID NO:3, nucleotides 76-783 of SEQ ID NO:3, nucleotides 79-783 of SEQ ID NO:3, nucleotides 82-783 of SEQ ID NO:3, nucleotides 85-783 of SEQ ID NO:3, nucleotides 88-783 of SEQ ID NO:3, nucleotides 91-783 of

20 SEQ ID NO:3, nucleotides 94-783 of SEQ ID NO:3, nucleotides 97-783 of SEQ ID NO:3, nucleotides 100-783 of SEQ ID NO:3, nucleotides 103-783 of SEQ ID NO:3, nucleotides 106-783 of SEQ ID NO:3, nucleotides 109-783 of SEQ ID NO:3 and nucleotides 112-783 of SEQ ID NO:3. In more particular embodiments, the amino terminal amino acid residue of the polypeptide is methionyl. Accordingly, the isolated

25 nucleic acid of the invention can have the sequence atg-nucleotides 52-783 of SEQ ID NO:3 or atg-nucleotides 112-783 of SEQ ID NO:3, for example. In a particularly preferred embodiment, the isolated nucleic acid encoding a polypeptide having thermostable cellulase activity has the sequence of nucleotides 52-789 of SEQ ID NO:3 or nucleotides 112-783 of SEQ ID NO:3.

In additional embodiments, the isolated nucleic acid of the invention encodes a family 12 glycosyl hydrolase having the amino acid sequence of EglA from *Pyrococcus furiosus* wherein one or more of the amino acid residues in the amino-terminal hydrophobic region and/or the linking moiety are deleted. For example, the isolated 5 nucleic acid can have the sequence of nucleotides 139-1041 of SEQ ID NO:4 or the sequence of nucleotides 229-1041 of SEQ ID NO:4.

The nucleic acids described herein can be amplified by methods known in the art. For example, amplification can be accomplished by the polymerase chain reaction (PCR). See generally *PCR Technology: Principles and Applications for DNA 10 Amplification* (ed. H.A. Erlich, Freeman Press, NY, NY, 1992); *PCR Protocols: A Guide to Methods and Applications* (eds. Innis, et al., Academic Press, San Diego, CA, 1990); Mattila et al., *Nucleic Acids Res.* 19:4967 (1991); Eckert et al., *PCR Methods and Applications* 1, 17 (1991); PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Patent 4,683,202. Other suitable amplification methods include the ligase chain 15 reaction (LCR) (see Wu and Wallace, *Genomics*, 4:560 (1989), Landegren et al., *Science*, 241:1077 (1988), transcription amplification (Kwoh et al., *Proc. Natl. Acad. Sci. USA*, 86:1173 (1989)), and self-sustained sequence replication (Guatelli et al., *Proc. Nat. Acad. Sci. USA*, 87:1874 (1990)) and nucleic acid based sequence amplification (NASBA).

20 The invention includes recombinant constructs comprising an isolated nucleic acid as described herein operably linked to at least one regulatory sequence. Generally, the isolated nucleic acid is joined (e.g., ligated, inserted) to a suitable vector, such as a plasmid or viral vector that includes an origin of replication, a selectable genetic marker and/or sequences which allow the insert nucleic acid to be expressed (transcribed 25 and/or translated). For example the recombinant construct can be an expression vector containing a nucleic acid sequence encoding a polypeptide described herein that is operably linked to at least one regulatory sequence. Many expression vectors are commercially available, and other suitable vectors can be readily prepared by the skilled artisan. As used herein, "operably linked" means that the nucleotide sequence is linked

to a regulatory sequence in a manner which allows expression (e.g., transcription and/or translation) of the nucleic acid sequence. Regulatory sequences are art-recognized and are selected to produce the polypeptide or active derivative or fragment thereof.

Accordingly, the term "regulatory sequence" includes promoters, enhancers, ribosome binding sites, polyadenylation signals and other expression control elements which are described, for example, in Goeddel, *Gene Expression Technology: Methods in Enzymology 185*, Academic Press, San Diego, CA (1990). For example, regulatory sequences native to *R. marinus* can be employed to express Cel12A. Suitable expression vectors and regulatory elements can be selected to provide for the desired level of expression in a desired host cell. For example, the polypeptides of the present invention can be produced by ligating a nucleic acid encoding the polypeptide into a vector suitable for expression in an appropriate host cell (see, for example, Broach, *et al.*, *Experimental Manipulation of Gene Expression*, ed. M. Inouye (Academic Press, 1983) p. 83; *Molecular Cloning: A Laboratory Manual*, 2nd Ed., ed. Sambrook *et al.* (Cold Spring Harbor Laboratory Press, 1989) Chapters 16 and 17)). For example, where expression in *E. coli* is desired the vector can include the T7/lac promotor. Other suitable regulatory sequences for use in *E. coli*, other bacteria, fungi (yeast, molds), insect and/or mammalian cells are known in the art. Typically, expression constructs contain one or more suitable selectable markers. Suitable selectable genetic markers include, for example, genes which confer resistance to antibiotics such as the β-lactamase gene from Tn3, the kanamycin-resistance gene from Tn903, the chloramphenicol-resistance gene from Tn₉, and the like. Suitable origins or replication include, for example, Ori p, colE1 Ori and the like.

Recombinant Host Cells and Methods of Production

The invention also relates to recombinant host cells (e.g., prokaryotic, eukaryotic, archaeon) which comprise an expression vector or isolated nucleic acid as described herein. For example, cells which can comprise a vector or isolated nucleic acid of the invention (for example, as a result of transformation, transfection or transduction)

- include, but are not limited to, bacterial cells (e.g., *R. marinus*, *E. coli* (e.g., *E. coli* K12 strains), *Streptomyces*, *Pseudomonas*, *Bacillus*, *Serratia marcescens*, *Salmonella typhimurium*), fungi including yeasts (e.g., *Saccharomyces cerevisie*, *Pichia pastoris*) and molds (e.g., *Aspergillus sp.*), insect cells (e.g., Sf9) or mammalian cells (e.g., COS, 5 CHO). The construct (e.g., expression vector) can be introduced into the host cells using any suitable method (e.g., electroporation, transfection using calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection, infection, transduction).

The isolated nucleic acid molecules and vectors of the invention are useful in the 10 manufacture of the encoded polypeptide, as probes for isolating homologous sequences (e.g., from other bacteriophage species), as well as for detecting the presence of a nucleic acid of the invention in a cells.

The invention also relates to a method of producing (*in vitro*, *in vivo*) a 15 polypeptide having thermostable cellulase activity. For example, a nucleic acid encoding a polypeptide of the invention, or a construct comprising such nucleic acid, can be introduced into a suitable host cell by a method appropriate to the host cell selected (e.g., transformation, transfection, electroporation, infection), such that the nucleic acid is operably linked to one or more expression control elements (e.g., in a vector, in a construct created by processes in the cell, integrated into the host cell 20 genome). Host cells can be maintained under conditions suitable for expression (e.g., *in vivo* or *in vitro*, in the presence of inducer, suitable media supplemented with appropriate salts, growth factors, antibiotic, nutritional supplements, etc.), whereby the encoded polypeptide is produced. In additional embodiments, the polypeptide of the invention can be produced by *in vitro* translation of a nucleic acid that encodes the 25 polypeptide (e.g., a nucleic acid having a sequence described herein), by chemical synthesis (e.g., solid phase peptide synthesis) or by any other suitable method. If desired, the polypeptide having thermostable cellulase activity can be isolated (e.g., from the host cells, medium, milk). It will be appreciated that the method encompasses

expression of the polypeptide in a host cell of a transgenic animal or plant (see e.g., U.S. Patent Nos. 6,013,857, 5,990385, 5,994,616).

Uses for Polypeptides that have Thermostable Cellulase Activity

The polypeptides of the invention are useful in a variety of applications, such as industrial processes. For example, the polypeptides can be used to improve freeness and to remove inks, coatings, toners and colors from wood or paper pulp (see, e.g., U.S. Patent Nos. 6,066,233, 5,525,193 and WO 98/44189). The polypeptides of the invention can also be included in detergent compositions and to treat cellulose-containing textiles and garments to improve the feel of the fabric or to remove lint, for example (see, e.g., U.S. Patent Nos. 5,904,736, 5,792,641, 5,445,957). Additional uses for the polypeptides of the invention are in the treatment of fibrous crops, fruits and vegetables or grains to improve feed values or to extract starches (e.g., sugars) or other components of the crop, fruit, vegetable or grain being treated. A number of methods for treating crops, fruits, vegetables or grains with a cellulase are known in the art (see, e.g., U.S. Patent Nos. 5,948,454, 4,795,101, 4,371,552 and WO 97/23652).

EXAMPLE

MATERIALS AND METHODS

Bacterial strains

20 Nova Blue and BL21 (DE3) strains of *E. coli* (Novagen, Madison, WI) were used for cloning and expression of variants of Cel12A. The GE2205 (Institute of Biology, University of Iceland) strain of *E. coli* containing plasmid pET23bAH was used for expression of a *cel12A* gene (Halldorsdottir, S. et al., *Appl Microbiol Biotechnol*, 49:277-284 (1998)). Plasmid pET25b(+) (Novagen) was used for 25 expression of variants of the Cel12A protein.

Construction of plasmids and sequencing

A gene fragment encoding 223 amino acids of the Cel12A (starting at the 38th amino acid), named δ cel12A with introduced *NdeI* and *HindIII* restriction sites was obtained by PCR utilising pET23bAH plasmid (Halldorsdottir, S. et al., *Appl Microbiol Biotechnol*, 49:277-284 (1998)) as a template. The following primers were used for amplification of δ cel12A: forward synthetic oligonucleotide primer (*NdeI* site underlined): 5'-AGGACTCCATATGACCGTCGAGCTGTCGG-3' (SEQ ID NO:7), reverse synthetic oligonucleotide primer (*HindIII* site underlined): 5'-ACCTGAGAAGCTTCTGCACCGTTACGGA-3' (SEQ ID NO:8). AmpliTaq GoldTM (Perkin-Elmer AB, Foster City, CA) DNA polymerase and hot start PCR protocol of 35 cycles of denaturation at 95°C for 1 min, annealing at 60°C for 1 min and primer extension at 72°C for 1 min were used. PCR fragments were separated by agarose gel electrophoresis, purified using a QIAEX II kit (QIAGEN GmbH, Hilden, Germany), digested overnight with *Nde I* and *Hind III* and purified again using the QIAEX II kit.

The gene fragment encoding Cel12A with the amino terminal hydrophobic region (putative signal peptide (first 17 amino acids)) deleted, named cel12A(sp-) was amplified using the following primers: forward synthetic oligonucleotide primer (*NdeI* site underlined): 5'-AGCTCCATATTGCGACTGGCTTTCC-3' (SEQ ID NO:9) and reverse synthetic oligonucleotide primer (*HindIII* site underlined): 5'-ACCTGAGAAGCTTCTGCACCGTTACGGA-3' (SEQ ID NO:10) and purified as described above. The pET25b(+) vector was opened with restriction enzymes (*Nde I* and *Hind III*) and purified using QIAEX II kit. Inserts were cloned into appropriately opened vectors to produce plasmids: pET25 δ Cel12AH and pET25Cel12A(sp-)H. Plasmids were prepared using QIAGEN Mini Plasmid Kit. The presence of cloned inserts in the plasmids was confirmed by restriction analysis and partial sequencing by the dideoxy chain termination method using the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction (Perkin-Elmer).

All restriction enzymes and T4 ligase were from Life Technologies (Rockville, MD). The enzymes were used according to the manufacturer's protocols.

Culture conditions and protein production

For expression of variant forms of the cellulase, bacteria were grown in baffled flasks in LB medium containing ampicillin to $OD_{600} = 0.7$ and then induced with IPTG (final concentration 1mM). Growth was continued for an additional 2.5 - 3 hours. Cells were harvested by centrifugation. The cell pellet was resuspended in 20 mM Tris-HCl pH 7.4 / 20 mM imidazole / 0.5 M NaCl buffer. Disintegration of the cells was performed using a UP400S sonicator (Dr. Heilscher GmbH, Stahnsdorf, Germany) at 60 10 W cm⁻², 3 x 120 seconds on ice. The crude cell extract was centrifuged at 27,000 x g for 20 min at 4°C and the supernatant stored frozen in -20°C for later purification.

Fed-batch cultivation for production of the Cel12A protein was carried out as described (Nordberg, K.E. *et al.*, *J. Ferment. Bioeng.*, (in press, 2000)). Bacteria were grown until the OD_{600} reached 32 and induced by addition of IPTG (final concentration 0.5 mM). Growth was continued for an additional 90 min. Whole fermentation culture was run three times on a Gaulin high-pressure homogenizer (APV-Schröder GmbH, Lübeck, Germany) at 700 atm to disintegrate the cells. The cell extract was centrifuged (27,000 x g, 4 °C, 15 min) and the supernatant frozen at -20°C and stored for purification.

20 Protein purification

Crude cell extracts containing variant Cel12A proteins were heat-treated at 65°C for 30 min, centrifuged at 27,000 x g for 15 min and the supernatants were loaded onto a chromatography column (crude extracts containing full-length Cel12A were not heat-treated). Recombinant proteins were purified utilizing C-terminal 6xHisidine tags 25 and immobilized metal-ion affinity chromatography (IMAC) as described (Abou-Hachem *et al.*, *Biochem. J.*, 345:53-60 (2000)). The eluate was dialyzed three times for several hours, against 45 volumes of 20 mM Tris-HCl pH 7.5 in dialysis tubes

with a molecular weight cut-off of 3.5 kD. Proteins were concentrated using Aquacide III (CALBIOCHEM, La Jolla, CA) according to the manufacture's protocol. Then, the concentrated protein solutions were centrifuged and the supernatants were stored at 4°C until used for further testing.

5 The histidine tag was removed from the purified polypeptides by digestion with carboxypeptidase-A type II from bovine pancreas (Sigma) for 1 hour at 37EC. Following digestion, the polypeptide solutions were loaded onto the affinity column and portions which did not bind (flow through) were collected. A portion of the flow through was analysed by SDS-PAGE to verify that the histidine tag had been removed.

10 Gel filtration chromatography was used to separate of cleaved and uncleaved Cel12A(sp-)H protein. A 50 cm column with internal diameter of 17 mm (Biorad), packed with Sephadex G-50 resin (Amersham Pharmacia Biotech AB, Uppsala, Sweden) was used. The column was run using 20 mM Tris-HCl pH 7.5.

Protein characterization

15 Protein production was analysed by sodium dodecyl sulphate polyacrylamide electrophoresis (SDS-PAGE) in 12.5 % gels using the method of Laemmli (Laemmli, U.K., *Nature*, 227:680-685 (1970)). Proteins were visualized by staining with Coomassie brilliant blue G250 (Merck, Darmstadt, Germany). Enzyme activity was detected using a 1 % (w/v) agarose overlayer gel containing 0.02 % (w/v)

20 carboxymethyl cellulose (CMC). The SDS/PAGE gels were washed with phosphate buffer pH 7.0 containing 1% Triton X-100 (t-octylphenoxypolyethoxyethanol, Merck) for 20 min. Thereafter, the gels were washed with phosphate buffer pH 7.0, covered with the overlayer gel and incubated for 2 hours at 65°C. Then, the agarose gels were stained in 1 % (w/v) Congo red solution. Excess dye was removed by washing with 1

25 M NaCl.

The dinitrosalicylic acid (DNS) stopping method was used for enzyme activity measurements. Samples were incubated with 0.9 % (w/v) CMC in 20 mM Tris-HCl pH 7.5 at 65°C for about 20 minutes or about 30 minutes. The enzymatic reactions were

stopped by adding 1.5 volume of DNS-solution (1% DNS / 0.2% phenol / 0.05% Na₂SO₃ / 1% NaOH / 20% Na-K-tartrate) to the samples and boiling the samples for 15 minutes. The amount of reducing sugars released was measured in 96 well microtiter plates by absorbance at 550 nm, using glucose solutions as standards.

5 CMC, phosphoric acid swollen cellulose (PASC), birch wood xylan, lichenan, locust bean gum and guar gum (all SIGMA, St. Louis, MO) and Konjak (Megazyme International Ltd.) were used for enzyme substrate specificity tests. Temperature optima were determined by running the activity assay at different temperatures ranging from 40°C to 105°C in 20 mM Tris-HCl pH 7.5 for 20 minutes. pH optima were studied by
10 running the activity assay in 0.1 M citrate/phosphate buffer (pH ranging from 3.0 to 6.0), 0.1 M sodium phosphatebuffer (pH ranging from 6.0 to 7.0), 50mM Tris-HCl buffer (pH ranging from 7.0 to 9.0) and glycine-NaOH buffer (pH ranging from 9.0 to 10.0) at 65°C for 30 min. Temperature stability was examined by determining residual enzymatic activity after incubating the proteins in absence of substrates at 65°C, 85°C
15 and 90°C for predetermined periods of time.

DNA and protein sequence analysis

A few Internet data banks and net tools were utilized for primary sequence analysis and secondary and tertiary structure prediction. BLAST 2.0 (Altschul *et al.*, *Nucleic Acids Research*, 25:3389-3402 (1997); Altschul *et al.*, *J Mol Bio*, 215:403-410 (1990)) which is available on a server of the National Center for Biotechnology Information - <http://www.ncbi.nlm.nih.gov/>) was used to investigate related sequences. Primary structure analysis was done using tools and databases available on the ExPASy Molecular Biology Server (<http://www.expasy.ch/>), such as PROSITE (Hofmann *et al.*, *Nucleic Acids Research*, 27:215-219 (1999); Bairoch A., *Nucleic Acids Research* 20 Suppl:2013-2018 (1992)) and SignalP (Nielsen H. *et al.*. *Protein Engineering*, 10:1-6 (1997)).

Differential scanning calorimetry (DSC)

Thermal transitions were measured by DSC using a VP-DSC microcalorimeter (MicroCal Inc., Northampton, MA), and the following parameters: scan rate 60 °C/h and temperature range from 25 °C to 130 °C. Different protein concentrations (ranging from 5 0.1 to 0.4 mg/ml) were used and measurements were performed in 20 mM Tris-HCl pH 7.5. Additional measurements were made using the same Tris buffer supplemented with 1mM CaCl₂, 0.5 % CMC or 0.5 % SDS.

RESULTS

Expression of full length Cel12A in E. coli

10 Cultivation of *E. coli* transformed with an expression plasmid encoding full length Cel12A in a shake-flask, revealed that induction of expression of the recombinant protein resulted in a decrease in optical density measured at 600 nm (Fig. 1), indicating that full length Cel12A induced cell lysis. Significant changes in bacterial morphology were noted after induction of Cel12A expression. Notably, the cultures
15 contained mostly long (up to 30 fold longer than normal *E. coli* cell) filamentous bacteria and multiple-cell clumps. Production of the cellulase (i.e., Cel12A) was extremely low due to the toxicity of the full length protein, and no clear recombinant protein band was visible on SDS-polyacrylamide gels (Fig. 2). However, two faint bands were detected on an activity stained over-layer gel. The second band detected
20 using the activity over-layer gel was probably produced by cleavage of Cel12A within linker region by bacterial proteases. Similar results were obtained when full length Cel12A was expressed in *E. coli* at 30°C. Specifically, no Cel12A was detected by SDS-PAGE, however no significant decrease in optical density was noticed.

To obtain enough protein for further tests the protein was produced using
25 fed-batch cultivation. However, induction of expression at high cell density led to a decrease in optical density that was associated with intensive foaming and increased culture viscosity, hallmarks of cell lysis. As in the shake-flask cultures, outgrowth of bacteria was eventually observed in cultures maintained under growth conditions. The

cultivation was stopped 2.5 hours after induction. Enzymatic activities (measured with DNS-stopping method) found in the cell pellet and in the supernatant were about equal. Thus, the Cel12A protein was purified from the entire batch culture (cells and media) to avoid protein lost. The Cel12A was purified by IMAC chromatography without prior
5 heat-treatment of crude cell extract. Partially purified protein was then heat-treated. Intensive precipitation of recombinant protein occurred upon heating, resulting in very low yield of pure Cel12A.

The purified full length Cel12A protein was not stable at 4°C and lost activity after several weeks of storage.

10 *Sequence analysis of the cel12A gene*

Properties of the Cel12A based on sequence analysis were predicted using ProtScale (<http://www.expasy.ch/cgi-bin/protscale.pl>). Amino acid sequence profiling using an optimised matching hydrophobicity (OMH) scale (Sweet, R.M. *et al.*, *J Mol Biol*, 171:479-488 (1983)) demonstrated that the N-terminal part of Cel12A is the most
15 hydrophobic region of the molecule. This hydrophobic region is connected to a short and less hydrophobic region. Profiling using the average flexibility index (Bhaskaran, R. *et al.*, *Int J Pept Protein Res*, 32:242-255 (1988)) showed that the first several amino acids of the protein (amino terminal amino acids) could form highly rigid secondary structure in the protein. Additionally, the hydrophobic amino terminal region was
20 followed by the most flexible region of the protein. The flexible region comprises a doublet of glutamic acid and proline that is repeated four times ([EP]₄). These studies revealed that Cel12A includes a catalytic domain and a hydrophobic N-terminal region that are linked through a flexible linker moiety (Fig. 3A). The amino-terminal region (first 38 amino acids) was shown to be toxic when expressed in BL21(DE3) bacteria
25 (Fig. 1).

Expression of Cel12A variants

To overcome bacterial host death during expression of the Cel12A, variant proteins were designed. (See schematics of proteins presented in Figs. 3A-3D.) A gene fragment encoding the catalytic domain (δ Cel12AH) downstream from the [EP]₄ linker was cloned under the control of T7/lac promoter in plasmid pET25b and expressed in *E. coli* BL21(DE3). The variant protein accumulated in cytoplasm of the host bacteria and no bacterial lysis was observed (Fig. 1). The growth rate of the bacteria was slightly inhibited due to the intensive production of the recombinant variant protein which accounted for about 40 % of total protein content of the cells (Fig. 2). The variant protein, δ Cel12A, did not precipitate when incubated at 65°C and retained activity on CMC as assessed by overlayer gel test.

A DNA fragment encoding a variant Cel12A that lacked the signal peptide (first 17 amino acids) was cloned into the pET25b plasmid and expressed in *E. coli*. Bacteria effectively produced active protein without cell lysis. However, the recombinant variant cellulase, Cel12A(sp-)H, was partially cleaved by bacterial protease and two bands were observed on SDS-polyacrylamide gels (Fig. 2), as well as on activity gels. Both variant cellulases were stable, and were stored at 4°C for several weeks.

Characterization of Cel12A and variants

The full-length cellulase expressed in *E. coli* has been characterised (Halldorsdottir, S. et al., *Appl Microbiol Biotechnol*, 49:277-284 (1998)). However, all activity tests described herein were conducted using full-length Cel12A and all variants. The full-length enzyme and all variants were rested with and without the His-tag (His₆), and no differences in properties were observed. The effect of temperature on activity was investigated by incubating the proteins at temperatures ranging from 40°C to 105°C and then assaying for enzymatic activity. The activity of full-length Cel12A and Cel12A(sp-)H increased up to 105°C, while Cel12AH displayed maximal activity at about 90°C (Table 1). The variant forms of the cellulase retained 95% - 100% of their initial activity after 16 hours at 85°C. The half-life of activity at 90°C for full-length

Cel12A was 3 hours, for Cel12AH was 2 hours and for Cel12(sp-)H was 5 hours. The pH optima for the full-length enzyme and the variants were similar. All proteins were active over a broad pH range and expressed over 40% of maximal activity at pH ranging from about 4.0 to about 8.0 and over 20% of maximal activity at pH 10.

- 5 The variant Cel12A proteins had the same substrate specificities as full-length Cel12A protein and hydrolysed soluble polysaccharides with β 1-4 and β 1-3 - β 1-4 linkages. The variants proteins hydrolysed CMC, lichenian, glucomannan and had highest level of enzymatic activity when assayed using lichenian (7.2 U/mg). The cellulases had very low activity on Avicel and were not active on xylan and
10 galactomannan. The variant cellulases had specific activities on CMC that were about 3 to about 4 times higher than the specific activity of the full-length protein (Table 1).

Table 1

	Optimal temperature for catalysis (°C)	Tm/Tm* (°C)	specific activity on CMC (U/mg)	T _{1/2} at 90 °C (hours)
Cel12A	>105	aggregates/120.0	0.7	3
Cel12AH	90	94.5/106.6	2.7	2
Cel12A(sp-)H	>105	102.9/NE	3.1	5
5 Cel12A(sp-)	>105	103.2/120.0	3.1	Retained 80% activity after 16 hours 45 minutes at 100°C

NE - not examined

Tm - unfolding temperature in 20 mM Tris-HCL pH7.5

Tm* - unfolding temperature in 20 mM Tris-HCL pH7.5/0.5% SDS

Table 2

Sample	Relative Catalytic Activity	
	no SDS	with 0.5% SDS
Cel12A	0.7	1
δCel12AH	1	0.86
5 Cel12A(sp-)H	1	0.94

DCS studies

- Intensive aggregation of the Cel12A (expressed as fluctuations of the Cp value), starting at temperatures of 65°C - 70°C were observed in 20 mM Tris-HCl pH 7.5, and no thermal transition peaks could be detected. The variant δCel12A unfolded at 94.5°C 10 when studies under the same conditions (Fig. 5), and no aggregation was noted up to 105°C. The thermal denaturation of δCel12A was irreversible. Thermal transition of CelA(sp-)H occurred at 102.9°C (Fig. 5), and thermal denaturation was irreversible. In contrast to xylanase, Ca²⁺ had no stabilizing effect on the cellulases. However, the stability of the proteins was slightly enhanced by substrate (3°C for δCel12AH).
- 15 All forms of the cellulase were stabilized by 0.5 % (w/v) SDS. In addition, the detergent stabilized and prevented aggregation of full-length Cel12A (Cel12A underwent thermal transition at 120°C in the presence of 0.5% SDS). Cel12A(sp-)H and δCel12AH unfolded at 120°C and 106.5°C, respectively, in presence of SDS. The thermal transitions for all tested cellulases were fully reversible when SDS was present.

Tween 20 (polyoxyethylenesorbitan monolaurate) non-ionic detergent did not stabilise the tested proteins at a concentration of 0.5 % .

Discussion

The endo-glucanase Cel12A from *R. marinus* has been cloned and produced in 5 *E. coli* (Halldorsdottir, S. et al., *Appl Microbiol Biotechnol*, 49:277-284 (1998)). Although the amount of protein produced in *E. coli* exceeded what could be obtained from *R. marinus* cultivations, the yield was comprehensively lower than expected. Particularly because expression was driven using a T7/lac promoter based system. Analysis of the primary structure of Cel12A revealed an explanation for the low 10 production yield, and interesting organisational features of the enzyme. Notably, the N-terminal contains a hydrophobic region that has features which are characteristic of signal peptides. The results of the study described herein demonstrate that this putative signal peptide is responsible for the toxicity of full-length enzyme. The optical density drop that was observed in cultures of *E. coli* when trying to express the first 38 amino 15 acid residues of the protein, was persistent several hours after induction suggesting that no post-induction cell division occurred.

Recombinant full-length Cel12A was not stable in solution or when heated to 65° C. In addition, the optimum growth temperature of *R. marinus* (65°C) caused extensive aggregation at moderately high protein concentrations. No clear thermal 20 transition of the full-length enzyme were observed on the calorimetric trace when the run was carried out without SDS, most likely because severe aggregation occurred before the protein was unfolded. Furthermore, a clearly visible aggregate was indeed observed when the sample was taken out of the DSC cell. However, a clear thermal transition (at 120°C) with no aggregation was observed when full-length Cel12A was 25 tested in the presence of 0.5 % SDS. Interestingly, the specific activity of the full-length enzyme was higher in the presence of SDS. In contrast, the presence of SDS lead to a

decrease in the specific activity of the variant lacking the first 17 amino acid residues (δ Cel12A) under the same conditions.

Cell associated glycosyl hydrolase activity has been reported earlier from *R. marinus* cultivations, where considerable activity was detected in the cell fraction
5 (Dahlberg, L. et al., *Appl. Microbiol. Biotechnol.*, 40:63-68 (1993)). To determine if Cel12A is cell associated, *R. marinus* was cultivated in the presence of CMC and the endoglucanase activity was assayed. Activity was detected in the sonicated cell fraction and in the supernatant fraction, indicating that at least some Cel12A is membrane associated.

10 The variants of Cel12A described herein were readily produced in large quantities by expression in *E. coli* and had improved stability and activity relative to full length Cel12A. In addition the variant proteins (e.g., δ Cel12AH, Cel12A(sp-)H) did not deviate substantially from the full-length enzyme in their pH optima or substrate specificities. This is consistent with the fact that the integrity of the catalytic core was
15 maintained, and the deletion of amino-terminal amino acids did not result in appreciable changes of the theoretically estimated isoelectric point of the enzyme. However, the deletion of the first 17 amino acid residues had a pronounced effect on the stability of the enzyme in aqueous media. As discussed earlier, the majority of the full-length enzyme after the first purification step was catalytically inactive, and heating the
20 samples at 65°C resulted in comprehensive loss of the enzyme due to aggregation. The hydrophobic residues of the putative signal peptide are likely to be solvent exposed and consequently would comprise the thermodynamic driving force for aggregation. Accordingly, heating the full-length protein can accelerate the aggregation process, since hydrophobic interactions increase with temperature in this region.

25 Glycosyl hydrolases are typically modular proteins, comprised of catalytic and auxiliary modules separated by recognisable linker sequences. Linker sequences occur in a variety of lengths and amino acid compositions depending on their origin (Tomme, P. et al., *Cellulose Hydrolysis by Bacteria and Fungi*. in: R. K. Poole, ed., *Advances in*

Microbial Physiology, vol 37, London, Academic Press (1995)). Typically, linkers are rich in prolines, hydroxy amino acids, alanine or glycine, and the arrangement of these amino acids imparts flexibility necessary for their function. The putative signal peptide and the catalytic module of Cel12A are separated by a typical linker sequence. The four 5 times repeat of glutamic acid and proline which preceding the catalytic core of the enzyme is reminiscent of the linkers that separate the different modules of the xylanase, Xyn10A from *R. marinus* (Nordberg, K.E. *et al.*, *Biochimica et Biophysica Acta*, 1353:118-124 (1997)). In addition this structure (i.e., a linker sequence that links the putative signal peptide and the catalytic module) is shared with another family 12 10 glycosyl-hydrolase from the hyperthermophilic archaeon *Pyrococcus furiosus* (Bauer, M.W. *et al.*, *J Bacteriology*, 181:284-290 (1999)).

The study described herein demonstrates that variant cellulases, that have the amino acid sequence of a thermostable cellulase wherein one or more amino acids which are not part of the catalytic domain of the enzyme are deleted, can be more easily 15 produced and have improved stability and/or catalytic activity relative to certain full-length cellulases.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the 20 scope of the invention encompassed by the appended claims.